How Does Amgen Stock Compare With Peers?
Amgen‘s stock has delivered strong returns over the past year, but how does it truly measure up against peers amidst a challenging biopharma landscape? A closer look reveals superior revenue growth and robust free cash flow, supported by a strong pipeline and strategic acquisitions. However, upcoming patent expirations for key products like Prolia and Xgeva, alongside intense market competition, could temper its near-term upside.
- AMGN’s 24.1% operating margin, while high, trails GILD (38.3%), reflecting post-acquisition integration costs affecting profitability.
- AMGN’s 10.6% revenue growth, outpacing peers, is driven by strong demand for new drugs and Horizon acquisition synergies.
- AMGN’s 28.1% gain and 21.7 PE reflect investor confidence, but GILD’s 34.8% return highlights stronger performance from its HIV portfolio.
Here’s how Amgen stacks up across size, valuation, and profitability versus key peers.
| AMGN | ABBV | GILD | REGN | BIIB | |
|---|---|---|---|---|---|
| Market Cap ($ Bil) | 185.8 | 407.3 | 155.4 | 75.0 | 26.5 |
| Revenue ($ Bil) | 36.0 | 59.6 | 29.1 | 14.2 | 10.1 |
| PE Ratio | 21.7 | 171.5 | 17.0 | 12.7 | 12.8 |
| LTM Revenue Growth | 10.6% | 7.4% | 2.8% | 2.9% | 4.8% |
| LTM Operating Margin | 24.1% | 24.1% | 38.3% | 26.7% | 24.8% |
| LTM FCF Margin | 32.1% | 33.0% | 31.5% | 27.2% | 22.5% |
| 12M Market Return | 28.1% | 31.3% | 39.2% | -2.9% | 12.4% |
For more details on Amgen, read Buy or Sell AMGN Stock. Below we compare AMGN’s growth, margin, and valuation with peers across years
Revenue Growth Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| AMGN | 10.6% | 18.6% | 7.1% | 1.3% |
| ABBV | 7.4% | 3.7% | -6.4% | 3.3% |
| GILD | 2.8% | 6.0% | -0.6% | -0.1% |
| REGN | 2.9% | 8.3% | 7.8% | -24.3% |
| BIIB | 4.8% | -1.6% | -3.3% | -7.4% |
Operating Margin Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| AMGN | 24.1% | 21.7% | 28.0% | 36.3% |
| ABBV | 24.1% | 21.1% | 24.9% | 32.4% |
| GILD | 38.3% | 36.5% | 32.5% | 40.2% |
| REGN | 26.7% | 28.8% | 32.3% | 41.0% |
| BIIB | 24.8% | 22.9% | 18.6% | 28.5% |
PE Ratio Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| AMGN | 21.7 | 34.2 | 22.9 | 21.6 |
| ABBV | 171.5 | 73.5 | 56.3 | 24.2 |
| GILD | 17.0 | 240.0 | 17.8 | 23.5 |
| REGN | 12.7 | 17.4 | 23.7 | 17.8 |
| BIIB | 12.8 | 13.6 | 32.2 | 13.2 |
Still not sure about AMGN stock? Consider portfolio approach.
Multi Asset Portfolios Offer More Upside With Less Risk
Stocks soar and sink but bonds commodities and other assets balance the ride. A multi asset portfolio keeps returns steadier and reduces single market risk.
The asset allocation framework of Trefis’ Boston-based, wealth management partner yielded positive returns during the 2008-09 period when the S&P lost more than 40%. Our partner’ strategy now includes Trefis High Quality Portfolio, which has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices